The FDA cleared an implant that stimulates a nerve in the chest that prompts the diaphragm to restore breathing.
LivaNova snagged FDA approvals for a pair of devices for the treatment of drug-resistant epilepsy.
While Animas users were invited to switch to a Medtronic pump, Insulet is offering them a trial of its insulin "pod."
Allegro Investment Fund led a $10 million series C that will boost commercialization and development of Sight Sciences' dry eye and surgical devices.
Novartis’ Alcon earned a CE mark for its automated, disposable, preloaded intraocular lens delivery system.
Johnson & Johnson's Animas is halting the manufacturing and sales of its insulin pumps effective immediately.
The nod from the FDA clears all blood collection establishments to follow its guidance and test for the virus.
Henry Schein will market Cerebral Assessment Systems' screening device that detects early signs of dementia.
EarlySense is launching an under-the-mattress, contact-free device that tracks female fertility.
The series B equips Recursion to move beyond its initial focus on repurposing by applying its technology to the discovery of novel targets and drugs.